Pharmaceutical R&D Productivity: The Role of Alliance

Authors

  • Sarah Kruse Rutgers Business School Blanche and Irwin Lerner Center for the Study of Pharmaceutical Management Issues
  • Mark Slomiany Rutgers Business School
  • Rema Bitar Rutgers Business School
  • Sarah Jeffers Rutgers Business School
  • Mahmud Hassan Rutgers Business School

DOI:

https://doi.org/10.5912/jcb632

Keywords:

Productivity, Alliance, CRO, Pharmaceutical, Biotechynology, Big Data

Abstract

In recent years, the major research-intensive biopharmaceutical companies (big pharma) have come face to face with a perfect storm of eroding profit margins from blockbuster expiration and generic competition coupled with growing R&D expenses and declining advances in truly novel therapeutics. With long-term research divisions shed in favor of short-term outsourcing options and with public good will at historic lows, industry innovators have sought to reinvent the model of big pharma, its relationship in public-private partnerships, and the role of technology and technology policy in reform. In this paper, we highlight a number of the major alliances reshaping the industry and the role of government, research institutions, and other players in the public-private interface in these endeavors. In particular, this paper looks beyond traditional biotechnology parternships and focuses instead on the developing consortia between biopharmaceutical companies and with clinical research organizations and academic institutions. We examined each alternative model of alliance, identified specific hurdles and potentials for increased productivity.

Author Biographies

Sarah Kruse, Rutgers Business School Blanche and Irwin Lerner Center for the Study of Pharmaceutical Management Issues

is currently attending Rutgers Business School for her MBA with concentrations in Pharmaceutical Management and Supply Chain Management. While at Rutgers she has worked as a Lerner Center Research Associate. In addition, she spent this summer working at Johnson & Johnson in their Procurement Leadership Development Program. In that position she worked on a category purchasing strategy for pharmaceutical research and development information technology. Her past experience was at a Contract Research Organization specialized in dermatology called Cu-Tech where she worked as a Clinical Research Associate.

Mark Slomiany, Rutgers Business School

is a graduate of Washington & Lee University, the Medical University of South Carolina, and Rutgers Business School, Mark holds a BA in biology and geology, a PhD in molecular biology, and an MBA in pharmaceutical management and finance. As a professor and scientist, Mark has held faculty positions at the Medical University of South Carolina, Medical College of Georgia, and the New York University School of Medicine. Retaining an adjunct faculty appointment at the Medical University of South Carolina, Mark currently serves as an industry analyst for the investment bank Bradley Woods & Co. and strategy consultant for MPEG LA.

Rema Bitar, Rutgers Business School

is currently pursuing an MBA at Rutgers Business School with concentrations in Marketing and Pharmaceutical Management. Earlier she worked at Merck & Co, there, she generated novel compounds in the pursuit of drug candidates for various therapeutic areas. She is a Research Associate with the Blanche and Irwin Lerner Center for the Study of Pharmaceutical Management Issues. She spent the summer of 2013 interning at Bayer Healthcare in their Women’s Healthcare Marketing Business Unit.

Sarah Jeffers, Rutgers Business School

is currently a MBA student at Rutgers Business School concentrating in Finance and Pharmaceutical Management and a Research Associate with the Lerner Center. She is currently employed at Merck & Co. Inc. as a MBA Finance Intern for the summer of 2013. In this position, Sarah is supporting Merck's franchise finance teams in a variety of different capacities including performing price sensitivity and product sales trend analyses. Prior to enrolling in Rutgers' MBA program, Sarah worked at Oxford Outcomes, Inc., a Health Economics and Outcomes Research firm. At Oxford Outcomes, she worked as an Operations Analyst where she supported the company in a finance capacity.

Mahmud Hassan, Rutgers Business School

is a Professor in the Department of Finance and Economic, Director, Pharmaceutical Management Program, and Director, Blanche and Irwin Lerner Center for the Study of Pharmaceutical Management Issues at the Rutgers Business School in New Jersey, USA. Dr. Hassan is a Health Economist, teaches Healthcare Finance and Pharmaceutical Management at the Rutgers Business School. His research papers were published in the Journal of Finance, Journal of Business, Journal of Health Economics, Health Affairs, Inquiry, Journal of Risk and Uncertainty, Journal of American Medical Association (JAMA), International Journal of Pharmaceutical and Healthcare Marketing, and several others.

References

REFERENCES

PricewaterhouseCoopers. Pharma 2020: The vision; Which path will you take? PricewaterhouseCoopers. June 2007; 1-52. Available from: BioValley, Basel, Switzerland. Accessed March 23, 2013.

Congressional Budget Office. Research and Development in the Pharmaceutical Industry. Congress of the United States, Congressional Budget Office. October 2006.

Terblanche N. New pharmaceutical product development: Barriers to overcome and opportunities to exploit. Journal Of Commercial Biotechnology [serial online]. July 2008;14(3):201-212. Available from: Business Source Premier, Ipswich, MA. Accessed March 9, 2013.

Kola I, Landis J. Can the Pharmaceutical Industry Reduce Attrition Rates? Nature Reviews Drug Discovery. August 2004;3:711-715.

Danzon, Patricia M.; Nicholson, Sean; and Pereira, Nuno Sousa. “Productivity in Pharmaceutical-Biotechonology R&D: the Role of Experience and Alliancesâ€, Journal of Health Economics, Vol. 24, No. 2, March 2005, pp: 317-339.

Hoang, HA; and Rothaermel, Frank T. “The Effect of General and Partner-Specific Alliance Experience on Joint R&D Project Performanceâ€, Academy of Management Journal, Vol. 48, No. 2, 2005, pp: 332-345.

Grabowski, Henry; and Kyle, Margaret. “Mergers and Alliances in Pharmaceuticals: Effects on Innovation and R&D Productivityâ€, in Economics of Corporate Governance and Mergers, ed. Gugler, Klaus and Yurtoglu, B. Burcin, published by Edward Elgar, Nov. 2008.

Schiele H. Early supplier integration: the dual role of purchasing in new product development. R&D Management [serial online]. March 2010;40(2):138-153. Available from: Business Source Premier, Ipswich, MA. Accessed February 21, 2013.

Yang S. Pharmaceutical innovation: AstraZeneca's experience in China. Mckinsey Quarterly [serial online]. March 2012;(1):93-95. Available from: Business Source Premier, Ipswich, MA. Accessed March 9, 2013.

Areddy J. Scientist Convicted of Stealing Merck Drugs. Wall Street Journal. June 2012. Available from: WSJ online. Accessed April 9, 2013.

Madhur Singh, Should Clinical Trials Be Outsourced? TIME, August 7, 2008, http://www.time.com/time/health/article/0,8599,1830334,00.html.

Nourmohammadi N. FierceCROs Top 5 Strategic CRO/Pharma Partnerships. Fierce CRO Web site. http://www.fiercecro.com/story/fiercecros-top-5-strategic-cropharma-partnerships/2012-06-14. June 14, 2012. Accessed April 5, 2013.

Miller J. CROs and CMOS Have Cause to Celebrate. Pharmaceutical Technology Europe [serial online]. October 2012;24(10):20-26. Available from: Business Source Premier, Ipswich, MA. Accessed April 4, 2013.

Getz KA. Insights from Today’s CRO Renaissance. Applied Clinical Trials Web Site. http://www.appliedclinicaltrialsonline.com/appliedclinicaltrials/article/articleDetail.jsp?id=334568&sk=&date=&%0A%09%09%09&pageID=2. June 1, 2006. Accessed April 5, 2013.

Getz KA. Successful Outsourcing: Tracking Global CRO Usage. Applied Clinical Trials Web Site. http://www.appliedclinicaltrialsonline.com/appliedclinicaltrials/article/articleDetail.jsp?id=619120&sk=&date=&%0A%09%09%09&pageID=5. August 17, 2009. Accessed April 5, 2013.

Kaitin K. 21st Century Bioinnovation. Pharmaceutical Technology [serial online]. June 2011;35(6):32. Available from: Business Source Premier, Ipswich, MA. Accessed April 12, 2013.

Collier R, McBride R. The Insider Perspective; Academic & Pharma Partnerships: Tapping the Ivory Tower for the Next Blockbuster. FiercePharma eBook. February 2012. Available from: FiercePharma. Accessed April 8, 2013.

Collier R, McBride R. Pitfalls, Horror Stories, and Cautionary Tales. Academic & Pharma Partnerships: Tapping the Ivory Tower for the Next Blockbuster FiercePharma eBook. February 2012. Available from: FiercePharma. Accessed April 8, 2013.

Toor S, McBride R. 20 Major Pharma-Academic Alliances in 2012. FierceBiotech Web Site. http://www.fiercebiotech.com/slideshows/20-major-pharma-academic-alliances-2012. Accessed March 9, 2013.

Richards D, Dalton B. Collaboration in research protocol design: A case study exploring knowledge creation for the pharmaceutical industry and prescribing physicians. Journal Of Medical Marketing [serial online]. July 2009;9(3):213-220. Available from: Business Source Premier, Ipswich, MA. Accessed March 9, 2013.

Blakeslee W. Licensing, partnering, strategic alliances and university relationships. Journal Of Commercial Biotechnology [serial online]. March 2012;18(2):68-71. Available from: Business Source Premier, Ipswich, MA. Accessed March 9, 2013.

Groves P, Kayyali B, Knott D, Van Kuiken S. The ‘big data†revolution in healthcare: Accelerating value and innovation. Center for US Health System Reform, Business Technology Office. McKinsey & Company. January 2013.

Hede K. Project Data Sphere to make cancer clinical trial data publicly available. Journal of the National Cancer Institute. July 21, 2013.

Bhattacharjee Y. Pharma Firms Push for Sharing Of Cancer Trial Data. Science. 338:29. October 2012.

http://www.transceleratebiopharmainc.org/ Accessed Aug 6, 2013

Downloads

Published

2014-04-01

Issue

Section

Articles